KEMBA BANYARD: Open Payments
NPI 1295080521 · MILWAUKEE, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,955 in 132 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $1,107 · 2025 $2,955
Food & beverage: $2,912Education: $42
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 31 | $634 |
| Otsuka America Pharmaceutical, Inc. | 18 | $471 |
| Lundbeck LLC | 30 | $445 |
| Janssen Pharmaceuticals, Inc | 9 | $272 |
| Tris Pharma Inc | 7 | $223 |
| Novo Nordisk Inc | 6 | $188 |
| Axsome Therapeutics, Inc. | 4 | $181 |
| Lilly USA, LLC | 8 | $174 |
| Teva Pharmaceuticals USA, Inc. | 7 | $139 |
| Collegium Pharmaceutical, Inc. | 4 | $82 |
Products named: REXULTI, FANAPT, INVEGA SUSTENNA, Dyanavel XR, Wegovy, Auvelity, MOUNJARO, ABILIFY ASIMTUFII.
Industry payments across WI — which companies pay providers there.
